- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00039117
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
A Phase I Study of G3139 ( NSC # 683428) in Combination With Cytarabine and Daunorubicin in Previously Untreated Patients With Acute Myeloid Leukemia (AML)>= 60 Years of Age
Panoramica dello studio
Stato
Condizioni
- Leucemia mieloide acuta dell'adulto con anomalie 11q23 (MLL).
- Leucemia mieloide acuta dell'adulto con Inv(16)(p13;q22)
- Leucemia mieloide acuta dell'adulto con t(16;16)(p13;q22)
- Leucemia mieloide acuta dell'adulto con t(8;21)(q22;q22)
- Leucemia mieloide acuta secondaria
- Leucemia mieloide acuta dell'adulto non trattata
Descrizione dettagliata
OBJECTIVES:
I. Determine the maximum tolerated dose of daunorubicin in combination with cytarabine and oblimersen in older patients with previously untreated acute myeloid leukemia.
II. Determine the qualitative and quantitative toxic effects of this regimen in these patients.
III. Determine the pharmacokinetics of oblimersen in this regimen in these patients.
IV. Determine the disease-free survival and overall survival of patients treated with this regimen.
V. Assess the spontaneous rate of apoptosis in leukemic blasts in patients before and after initiation of treatment with oblimersen.
VI. Determine therapeutic response (complete remission) in patients treated with this regimen.
OUTLINE: This is a dose-escalation study of daunorubicin. Patients are stratified according to disease status (primary vs secondary).
INDUCTION THERAPY: Patients receive oblimersen (G3139) IV continuously on days 1-10 and cytarabine IV continuously on days 4-10. Patients also receive daunorubicin IV daily on days 4-6.
Patients with bone marrow cellularity of at least 20% and at least 5% leukemic blasts at day 17 or evidence of refractory disease receive a second induction comprising G3139 IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5.
CONSOLIDATION THERAPY: Beginning no sooner than 14 days after hematologic recovery from induction therapy, patients receive G3139 IV continuously on days 1-8 and cytarabine IV over 4 hours on days 4-8. Patients receive a second course of consolidation therapy no sooner than 14 days after hematologic recovery from the first course.
Cohorts of 3-6 patients receive escalating doses of daunorubicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Patients are followed every 2 months for 2 years.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43210
- Ohio State University Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Histologically confirmed primary or secondary acute myeloid leukemia (AML)
- More than 20% bone marrow blasts
- Myelodysplastic syndromes (MDS) or a chronic myeloproliferative disorder antecedent to AML allowed
- Therapy-related AML allowed
- No acute promyelocytic leukemia
- At least 4 weeks
- Bilirubin no greater than 2 mg/dL
- ALT and AST no greater than 2 times upper limit of normal (unless directly attributable to AML)
- Creatinine no greater than 2.5 mg/dL
- Ejection fraction at least 50% by MUGA or echocardiogram
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- No allergy to any of the study medications
- No other uncontrolled concurrent illness
- No serious medical or psychiatric illness that would preclude giving informed consent
- Not pregnant or nursing
- Fertile patients must use effective contraception
- No prior therapy for primary AML except emergency leukapheresis
- No prior anthracyclines
- No prior chemotherapy for primary AML except hydroxyurea for hyperleukocytosis
- At least 3 months since prior chemotherapy for MDS or chronic myeloproliferative disorders antecedent to AML
- No other concurrent chemotherapy
- No concurrent corticosteroids as anti-emetics
- No concurrent steroids except for adrenal failure or septic shock
- No concurrent hormonal therapy except hormones for non-disease-related conditions (e.g., insulin for diabetes, tamoxifen or equivalent for breast cancer prevention or adjuvant treatment, or estrogens or progestins for gynecologic indications)
- No prior radiotherapy for primary AML except cranial radiotherapy for CNS leukostasis
- No concurrent palliative radiotherapy
- No concurrent whole brain radiotherapy
- No other concurrent investigational or commercial agents or therapies
- No concurrent cyclooxygenase-2 inhibitors
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: Arm I
INDUCTION THERAPY: Patients receive oblimersen (G3139) IV continuously on days 1-10 and cytarabine IV continuously on days 4-10. Patients also receive daunorubicin IV daily on days 4-6. Patients with bone marrow cellularity of at least 20% and at least 5% leukemic blasts at day 17 or evidence of refractory disease receive a second induction comprising G3139 IV continuously on days 1-8, cytarabine IV continuously on days 4-8, and daunorubicin IV on days 4-5. CONSOLIDATION THERAPY: Beginning no sooner than 14 days after hematologic recovery from induction therapy, patients receive G3139 IV continuously on days 1-8 and cytarabine IV over 4 hours on days 4-8. Patients receive a second course of consolidation therapy no sooner than 14 days after hematologic recovery from the first course. |
Studi correlati
Dato IV
Altri nomi:
Studi correlati
Altri nomi:
Dato IV
Altri nomi:
Dato IV
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
MTD of cytarabine and daunorubicin in combination with G3139, defined as the dose level just below the dose level at which DLT is observed in 2 patients, graded according to NCI CTC version 2.0
Lasso di tempo: Up to day 10
|
Up to day 10
|
|
Incidence of adverse events, graded according to NCI CTC version 2.0
Lasso di tempo: Up to 2 years
|
We will define the qualitative and quantitative toxicities in regard to organ specificity, time course, predictability, and reversibility.
|
Up to 2 years
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Sopravvivenza globale
Lasso di tempo: Fino a 2 anni
|
Fino a 2 anni
|
Pharmacokinetics of G3139
Lasso di tempo: During induction therapy on day 1 at hour 0 and 24hours after G3139 administration; day 4 at hour 73 before cytarabine administration; day 11 at hour 0 and .5, 1, 2, 4, 6, and 8 hours
|
During induction therapy on day 1 at hour 0 and 24hours after G3139 administration; day 4 at hour 73 before cytarabine administration; day 11 at hour 0 and .5, 1, 2, 4, 6, and 8 hours
|
Level of bcl-2 in circulating and/or marrow leukemic blasts before and after initiation of treatment with G3139
Lasso di tempo: Up to 18 weeks
|
Up to 18 weeks
|
Spontaneous rate of apoptosis in leukemic blasts before and after initiation of treatment with G3139
Lasso di tempo: Up to 18 weeks
|
Up to 18 weeks
|
Incidence of therapeutic response (complete remission [CR])
Lasso di tempo: Up to 2 years
|
Up to 2 years
|
Sopravvivenza libera da malattia
Lasso di tempo: Fino a 2 anni
|
Fino a 2 anni
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Guido Marcucci, Ohio State University
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per tipo istologico
- Neoplasie
- Leucemia
- Leucemia, mieloide
- Leucemia, mieloide, acuta
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Agenti antinfettivi
- Agenti antivirali
- Inibitori enzimatici
- Antimetaboliti, Antineoplastici
- Antimetaboliti
- Agenti antineoplastici
- Agenti immunosoppressivi
- Fattori immunologici
- Inibitori della topoisomerasi II
- Inibitori della topoisomerasi
- Antibiotici, Antineoplastici
- Citarabina
- Daunorubicina
- Oblimersen
Altri numeri di identificazione dello studio
- NCI-2012-01409
- U01CA076576 (Sovvenzione/contratto NIH degli Stati Uniti)
- OSU-0164
- NCI-4630
- CDR0000069353
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su analisi di laboratorio dei biomarcatori
-
ORIOL BESTARDCompletatoTrapianto di rene | Infezione da CMVSpagna, Belgio
-
Progenity, Inc.CompletatoSindrome di Down | Aneuploidia | Sindrome di DiGeorge | Sindrome di Turner | Sindrome di Klinefelter | Delezione cromosomica | Sindrome di Edwards | Sindrome di PatauStati Uniti
-
Vanderbilt University Medical Center4DMedicalCompletato
-
RWTH Aachen UniversitySconosciutoEmorragia subaracnoidea aneurismaticaGermania
-
Central and North West London NHS Foundation TrustBritish HIV Association (BHIVA)Non ancora reclutamentoInfezioni da HIV | Epatite B
-
Bakirkoy Dr. Sadi Konuk Research and Training HospitalReclutamento
-
University of MiamiAttivo, non reclutante
-
Universidad Miguel Hernandez de ElcheInstitut Català de la Salut; Andaluz Health Service; Osakidetza; Servicio Madrileño... e altri collaboratoriCompletatoMalattie professionaliSpagna
-
Rio de Janeiro State UniversityCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... e altri collaboratoriCompletatoMalattia cardiovascolare | Carenza di vitamina D | Condizioni correlate alla menopausaBrasile
-
RenJi HospitalSconosciutoCarcinoma a cellule squamose dell'esofagoCina